Arcutis Biotherapeutics Inc.

25.09+0.3700+1.50%Vol 403.34K1Y Perf 28.22%
Aug 16th, 2022 16:00 DELAYED
BID20.03 ASK27.60
Open24.61 Previous Close24.72
Pre-Market- After-Market24.38
 - -  -0.71 -2.83%
Target Price
53.17 
Analyst Rating
Strong Buy 1.10
Potential %
111.92 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
91.71 
Earnings Rating
Market Cap1.51B 
Earnings Date
4th Aug 2022
Alpha0.01 Standard Deviation0.19
Beta0.25 

Today's Price Range

23.890.00

52W Range

13.5926.13

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
0.93%
1 Month
3.68%
3 Months
28.47%
6 Months
56.62%
1 Year
28.22%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ARQT25.090.37001.50
AAPL173.03-0.1600-0.09
GOOG122.51-0.3700-0.30
MSFT292.71-0.7600-0.26
XOM91.46-0.8600-0.93
WFC46.060.31000.68
JNJ167.571.48000.89
FB196.640.99000.51
GE81.071.26001.58
JPM123.631.17000.96
 
Earnings HistoryEstimateReportedSurprise %
Q02 2022-1.38-1.315.07
Q01 2022-1.42-1.2710.56
Q04 2021-1.41-1.42-0.71
Q03 2021-1.09-1.14-4.59
Q02 2021-0.91-0.847.69
Q01 2021--0.76-
Q04 2020-0.89-0.7911.24
Q03 2020-0.95-1.01-6.32
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-1.38
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume403.34K
Shares Outstanding60.19K
Shares Float28.75M
Trades Count6.07K
Dollar Volume9.99M
Avg. Volume603.99K
Avg. Weekly Volume474.09K
Avg. Monthly Volume776.67K
Avg. Quarterly Volume561.21K

Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) stock closed at 25.09 per share at the end of the most recent trading day (a 1.5% change compared to the prior day closing price) with a volume of 403.34K shares and market capitalization of 1.51B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 54 people. Arcutis Biotherapeutics Inc. CEO is Todd Franklin Watanabe.

The one-year performance of Arcutis Biotherapeutics Inc. stock is 28.22%, while year-to-date (YTD) performance is 20.97%. ARQT stock has a five-year performance of %. Its 52-week range is between 13.59 and 26.13, which gives ARQT stock a 52-week price range ratio of 91.71%

Arcutis Biotherapeutics Inc. currently has a PE ratio of -4.90, a price-to-book (PB) ratio of 7.74, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -70.92%, a ROC of -75.03% and a ROE of -85.28%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Arcutis Biotherapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.38 for the next earnings report. Arcutis Biotherapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Arcutis Biotherapeutics Inc. is Strong Buy (1.1), with a target price of $53.17, which is +111.92% compared to the current price. The earnings rating for Arcutis Biotherapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Arcutis Biotherapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Arcutis Biotherapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 16.35, ATR14 : 1.64, CCI20 : 70.23, Chaikin Money Flow : -0.12, MACD : 0.71, Money Flow Index : 69.70, ROC : 5.82, RSI : 46.71, STOCH (14,3) : 84.21, STOCH RSI : 0.00, UO : 52.93, Williams %R : -15.79), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Arcutis Biotherapeutics Inc. in the last 12-months were: David W. Osborne (Sold 6 025 shares of value $128 886 ), Howard G. Welgus (Option Excercise at a value of $24 701), Howard G. Welgus (Sold 33 500 shares of value $720 823 ), Kenneth Lock (Sold 1 958 shares of value $33 833 ), Patricia A. Turney (Option Excercise at a value of $265 097), Patricia A. Turney (Sold 1 959 shares of value $33 851 ), Patrick Burnett (Sold 1 011 shares of value $17 032 ), Scott L. Burrows (Sold 13 283 shares of value $264 700 ), Todd Franklin Watanabe (Option Excercise at a value of $30 733), Todd Franklin Watanabe (Sold 33 412 shares of value $764 998 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (80.00 %)
4 (80.00 %)
5 (83.33 %)
Moderate Buy
1 (20.00 %)
1 (20.00 %)
1 (16.67 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.10
Strong Buy
1.10
Strong Buy
1.08

Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The firm's lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis.

CEO: Todd Franklin Watanabe

Telephone: +1 805 418-5006

Address: 2945 Townsgate Road, Westlake Village 91361, CA, US

Number of employees: 54

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

73%27%

Bearish Bullish

70%30%

TipRanks News for ARQT

Fri, 29 Jul 2022 17:55 GMT Mizuho Securities Believes Arcutis Biotherapeutics (ARQT) Still Has Room to Grow

- TipRanks. All rights reserved.

Sun, 10 Jul 2022 23:55 GMT Mizuho Securities Believes Arcutis Biotherapeutics (ARQT) Wont Stop Here

- TipRanks. All rights reserved.

Tue, 24 May 2022 15:56 GMT Arcutis Biotherapeutics (ARQT) Gets a Buy Rating from Mizuho Securities

- TipRanks. All rights reserved.

Tue, 22 Mar 2022 23:05 GMT Arcutis Biotherapeutics (ARQT) Received its Third Buy in a Row

- TipRanks. All rights reserved.

Tue, 18 Jan 2022 09:25 GMT Arcutis Biotherapeutics (ARQT) Receives a Buy from Mizuho Securities

- TipRanks. All rights reserved.

News

Stocktwits